The Global Antiplatelet Drugs Market Growth Accelerated By Increasing Burden Of Cardiovascular Diseases
![]() |
| Antiplatelet Drugs Market |
Antiplatelet drugs help in preventing blood clots which can
reduce the risk of heart attacks and strokes. They are widely used for patients
receiving coronary artery stents and those with conditions like coronary artery
disease or peripheral vascular disease. The increasing burden of cardiovascular
diseases is driving the demand for antiplatelet drugs globally.
The global Antiplatelet Drugs Market is estimated to be
valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period
2024 to 2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The adoption of combination antiplatelet therapy has increased
significantly over the past few years. Combination of antiplatelet drugs having
different mechanisms of action helps provide better protection against arterial
thrombosis without significantly increasing the risk of bleeding. Drugs like
aspirin and clopidogrel are commonly used in combination. The approval and
launch of newer oral antiplatelet drugs with improved efficacy and safety
profiles is also influencing the adoption of combination antiplatelet therapy.
This shift is expected to drive the demand for antiplatelet drugs during the
forecast period.
Segment Analysis
The global antiplatelet drugs market is dominated by the aspirin sub
segment. Aspirin is considered as the gold standard antiplatelet drug for most
of the indications due to its effectiveness and low cost. It is used for
prevention of cardiovascular diseases, thromboembolic stroke and myocardial
infarction. Aspirin is widely used drug for prevention of artery-clogging blood
clots thus prevents heart attacks, strokes and other cardiovascular problems.
Key Takeaways
The global
antiplatelet drugs market analysis is expected to witness high growth
over the forecast period of 2024 to 2031. The global Antiplatelet Drugs Market
is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit
a CAGR of 12% over the forecast period 2024 to 2031.
Regional
analysis -
Asia Pacific region currently dominates the global antiplatelet drugs market
and is estimated to be the fastest growing region during the forecast period.
High population, increasing awareness about cardiovascular diseases and growing
healthcare expenditures are some factors driving the growth of antiplatelet drugs
market in Asia Pacific region.
Key players related content
comprises - Key players operating in the antiplatelet drugs market are Chang
Chun Group, Covestro AG, Dow, and Hexio. Chang Chun Group is a leading
manufacturer of aspirin and clopidogrel tablets globally. Covestro AG provides
specialty chemicals for manufacturing of clopidogrel. Dow offers antiplatelet
drug excipients to various pharmaceutical companies. Hexio has strong presence
in Asia Pacific antiplatelet drugs market through its aspirin and clopidogrel
generics.
Get
more insights on this topic: https://www.newswirestats.com/antiplatelet-drugs-market-industry-insights-trends-antiplatelet-drugs-market/

Comments
Post a Comment